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Abstract 
It becomes increasingly accepted that a shift is needed from the traditional target-based 
approach of drug development to an integrated perspective of drug action in biochemical 
systems. We here present an integrative analysis of the interactions between drugs and 
metabolism based on the concept of drug scope. The drug scope represents the set of 
metabolic compounds and reactions that are potentially affected by a drug. We constructed 
and analyzed the scopes of all US approved drugs having metabolic targets. Our analysis 
shows that the distribution of drug scopes is highly uneven, and that drugs can be classified 
into several categories based on their scopes. Some of them have small scopes corresponding 
to localized action, while others have large scopes corresponding to potential large-scale 
systemic action. These groups are well conserved throughout different topologies of the 




There is a growing perception that the traditional approach for drug development has not been 
as effective as could be expected [1]. Although investments by pharmaceutical companies 
have been growing continuously in the last decades, the number of newly approved drugs has 
not followed the same trend [2,3]. Currently the main trend in drug design and development 
follows the target-based approach. The drug target is generally a single gene or gene product 
which has been clearly identified as having an action on the disease. Disease treatment seeks 
to modulate this action without affecting other processes in the organism. However, many 
diseases are multifactorial, and the current approach fails to take such systemic aspects into 
account [4]. The complex interactions between numerous molecular processes and pathways 
involved in diseases imply that any treatment targeting a local element will create secondary 
effects on the entire system. The lack of an integrative investigation of drug action can lead to 
either positive or negative systemic effects being missed. In the first case, the treatment only 
provides limited and localized cure for the disease while failing to address large-scale causes. 
In the second case, new drugs are developed with harmful side effects that are only revealed 
at a late stage of clinical studies. This problem of drug attrition is a major concern for the 
pharmaceutical industry and an important source of financial costs. Additional problems can be 
caused by side-effects resulting from combinations of several drugs, arising from unexpected 
interactions which were not revealed by local analysis. 
To increase the productivity of drug development and the efficiency of new drugs, there is thus 
a strong need to move beyond the investigation of drug action from the point of view of direct 
targets only, and to take into account the full network of interactions connecting the targets 
with the rest of the system. Drug development needs to be approached not only in terms of a 
molecular biology process, but also as a systems biology process [5,6,7,8]. This awareness has 
recently led to the completion of major studies revealing the large-scale interactions between 
drugs, drug targets and diseases from a network-based perspective [9,10,11,12,13]. However, 
these approaches did not unveil yet how specific drugs interact in biochemical systems, and 
new methods are needed to gain an integrated perspective of the mechanisms of drug action 
in complex systems. 
To this aim, we here introduce a new view of drug-metabolism interactions based on the 
concept of drug scope. The concept of a scope was previously developed in metabolic networks 
[14]. It uses an expansion process based on the principle that, for any reaction to take place, 
all necessary substrates must be present and the products of these reactions may in turn be 
used by other reactions. Starting from a set of seed compounds, reactions whose substrates 
are available in the seed set are iteratively added, resulting in the generation of a series of 
expanding networks. When no further reaction can be added, the final network obtained is 
defined as the scope of the seeds. The scope represents the set of all compounds that can in 
principle be synthesized from the seeds. This concept was already proven valuable in revealing 
features of the evolution of metabolic systems, leading notably to demonstrating how the shift 
from anoxic to oxic environments transformed the architecture of metabolic networks and how 
the availability of oxygen allowed an increase in biological complexity [15]. Recently, it was 
shown that features of scopes could also be linked to chemical structures and biological 
functions of the seeds [16]. 
We here extend the scope paradigm to drug-metabolism interactions. Many drugs target genes 
or gene products that are involved in metabolic functions. When a metabolic reaction is 
targeted by a drug, the concentrations of its substrates and products are affected as a result of 
drug action. Other reactions which use the products of the initial reactions are in turn affected 
by these perturbations. By iterative expansion, the entire scope of the initial substrates and 
products can in principle be affected by the drug. Basing on this principle, we thus introduce 
the concept of a drug scope defined by the following: the scope of a drug is the scope resulting 
from the expansion of a set of seed compounds containing the substrates and products of all 
metabolic reactions targeted by that drug. 
The drug scope essentially represents the largest network of possible action of a drug in a 
metabolic system. In the following sections, we show how drug scopes reveal new features of 
the systemic modes of drug action through a detailed analysis of the scopes of 276 human 
approved drugs from the DrugBank database [17] having metabolic targets. As scopes depend 
on the topology of the metabolic network used in the expansion process, we analyzed the 
action of each drug in four different systems: a human vs. a reference metabolic network 
consisting of the union of all organisms, and for each of those a reversible vs. an irreversible 
topology. Further details on the construction of drug scopes are provided in the Methods 
section. Our results show that the distribution of scopes is highly uneven and that they can be 
classified into different categories. Some drugs have small scopes associated to localized 
action, while others have large scopes associated to potential widespread systemic action. 
These classes are relatively well conserved throughout the four systems. A network of drug 
scopes, where scopes are connected when their Jaccard distance is smaller than a given 
threshold, confirms these characteristics, and a k-core decomposition algorithm reveals several 
highly connected central components as well as peripheral subgraphs. We subsequently 
analyzed the correlations between drug scopes and therapeutic properties of drugs, and show 
that therapies are not distributed uniformly but can often associated to specific groups of 
scopes, correlated to similar k-cores. Drug scopes therefore offer a new avenue to analyze 
drug-metabolism interactions and may provide valuable assistance to the drug development 
and assessment process. 
Results 
Drug scopes are highly uneven 
The first step in characterizing the properties of drug scopes consisted in analyzing the 
distribution of their sizes. In many cases multiple drugs have the same targets and these 
drugs automatically have the same scope. To avoid identical scopes to be counted several 
times, we beforehand selected a subset of scopes where only one representative of each group 
of identical scopes was kept, resulting in a group of 97 scopes which are all different. The 
distributions of sizes of these scopes are shown in Figure 1 for each of the four metabolic 
networks. 
Histograms reveal a highly heterogeneous distribution. Scope sizes are not distributed evenly, 
nor do they show any kind of regular distribution law. On the contrary, sizes are often 
concentrated around particular values: for example, in the reference reversible network there 
are 48 scopes of size comprised between 1920 and 1940. The presence of such peaks can be 
attributed to particular metabolites. It is known that the inclusion of ubiquitous metabolites 
has a strong influence on the size of scopes [18]. The most frequent of them is ATP, which 
together with water and oxygen generate a scope of 1929 compounds. The previously 
mentioned peak is thus clearly attributable to the presence of ATP. Nevertheless, it is 
remarkable that scopes do not exhibit larger variations around peaks. This observation 
suggests that drugs scopes can be separated into distinct and relatively homogeneous groups, 
where internal variations are small. 
The frequencies of occurrence of chemical compounds and reactions in drug scopes are plotted 
in Figures 2 and 3 respectively. These distributions are very irregular and do not follow any 
classical law either. Peaks can be observed at some values, separated by intervals of zero 
frequency. Such distributions can be explained by the fact that scopes tend to grow through 
the incorporation of groups of metabolites, ubiquitous metabolites bringing large numbers of 
other metabolites with them. The sharp peaks observed at some high values, particularly for 
the reference network, are a further indication that groups of very similar scopes exist. Each of 
these peaks corresponds to a group of scopes containing many of the same compounds and 
reactions. It was thus desirable to use clustering methods to reveal such groups of drugs. 
Scopes reveal four main categories of systemic drug action 
We clustered drug scopes using the Jaccard distance as a measure of dissimilarity between 
scopes (see Methods). In the reference reversible network, four clusters of drug scopes were 
obtained, whose main properties are listed in Table 1. In order to highlight the main features 
and differences between these clusters, we constructed the consensus scope of each cluster. 
The consensus scope is the set of compounds present in at least 50% of all scopes of a cluster 
(see Methods). Consensus scopes of the four clusters are plotted over a genome scale 
metabolic map in Figure 4. 
Clear differences can be observed between these four drug clusters. Cluster I is composed of 
drugs whose scope is very small. These scopes only slightly differ from the minimal scope 
induced by water and oxygen alone. When only water and oxygen are used as seeds and 
cofactors are allowed, a minimal scope of 12 compounds is obtained. The average size of 
scopes in cluster I is 15, and the size of their consensus scope is 12. These scopes thus mainly 
consist of the minimal scope with the addition of a handful of other compounds. These 
additional compounds are isolated and poorly connected to the rest of the metabolic network, 
as they do not further increase the size of the scope. Drugs belonging to cluster I are therefore 
only able to affect a limited and specific part the metabolic network. Their action is not allowed 
to propagate beyond the intended target and should be mainly local. 
Cluster III contains the same minimal component induced by water and oxygen, but 
additionally contains a larger component centered on arachidonic acid metabolism. This 
component, which can be seen at the left-hand side of the genome scale metabolic map 
(Figure 4), is absent from the three other clusters. Interactions of certain drugs with 
arachidonate metabolism have long been known and this pathway is particularly important in 
anti-inflammatory treatments [19,20]. 
Clusters II and IV on the contrary contain large scopes spreading through many parts of the 
metabolic network. Drugs belonging to these clusters can therefore in principle affect a wide 
area of metabolism and potentially have widespread systemic effects. Such dramatic increase 
in the size of scopes can be achieved by the inclusion of particular metabolites. For example, 
Raymond and Segrè [15] showed that the availability of oxygen leads to a major expansion of 
the size and complexity of metabolic systems. Although oxygen and water where assumed to 
be always available in our analysis, similar increases can be achieved by the inclusion of other 
metabolites. The most important of them is ATP, which explains the distinction between cluster 
II and IV: ATP is present in all scopes of cluster II but absent from the scopes of cluster IV. It 
is worth noticing that ATP does not have the largest scope of all metabolites though: this 
position is held by adenosine 5'-phosphosulfate [18], which is only present in a small number 
of scopes of cluster II (16 out of 163). The size of a compound’s scope alone is thus not a 
determining factor for its recurrent occurrence in drug scopes. Pyruvate plays a major role too 
in separating different clusters, as it is present in clusters II and IV, but absent from clusters I 
and III. 
Drug categories are conserved in different networks 
The scope construction process fundamentally depends on the topology of the underlying 
metabolic network. We therefore conducted the same analysis in four different networks: a 
reference network consisting of the union of all organisms vs. a human metabolic network, and 
in each of those a reversible vs. an irreversible topology (see Methods). Clustering of drug 
scopes in these other networks resulted in more clusters being found than in the reference 
reversible network (Tables 2, 3, 4). However, most of these new clusters are very small, 
containing only in a handful of drugs. They would fall into one of the four main clusters if the 
cutoff were increased. The detailed composition of clusters is provided for the four networks in 
Supplementary File 2. 
The four main clusters are still present and exhibit similar characteristics as in the reference 
reversible network. Although the average size of scopes is smaller in irreversible and human 
networks than in the reference reversible case (which is natural because scopes in irreversible 
and human networks are necessarily subsets of scopes in the reference reversible network), it 
is worth noticing that the consensus scopes of the four main clusters remain very similar to 
their reference reversible counterparts (Figures 2, 3, 4). Overlaps between consensus scopes 
from different clusters were made apparent by Venn diagrams (Figure 5). Groups consisting of 
large (II and IV) and small scopes (I and III) are clearly distinguishable in the reference 
reversible network. In the reference irreversible network, this pattern is well conserved despite 
additional small clusters appearing. In human networks, more complex overlapping patterns 
emerge but two groups of large scopes are still present. 
More significantly, the drug composition of the four main clusters is well conserved throughout 
the different networks (Figure 6). Cluster III is even 100% conserved in all four networks. The 
only significant difference appears with cluster IV, which is less conserved in the human 
irreversible network. The latter network is the less densely connected of all four, therefore 
emphasizing the dependence of drug scopes on local targets and leading to a higher scattering 
of scopes. Table 4 shows that this network has a large number of very small clusters, making 
it more difficult to identify large groups of drugs with common properties as a result. On the 
other side, this network is the most appropriate when it comes to identifying highly specific 
drug-metabolism interactions, as scopes tend to be more restricted to the immediate 
neighborhood of drug targets. 
Drug scopes are correlated to therapeutic properties 
As drug scopes are related to features of the systemic modes of drug action, a fundamental 
question was to determine whether the properties of drug scopes could be linked to 
therapeutic properties of the drugs themselves. We consequently analyzed the distribution of 
therapeutic properties, defined by level 1 tags of the ATC classification (see Methods), in the 
four main groups of drugs identified by clustering of their drug scopes. As shown in Figure 7, 
the repartition of therapies is not uniform in the four groups. While clusters II and IV show 
relatively similar compositions in therapies, they together strongly differ from clusters I and 
III. 55% of drugs in cluster III belong to the musculo-skeletal system (M) category, and 77% 
of all class M drugs belong to cluster III. Cluster I is dominated by antiinfectives (A) and 
sensory organs (S) drugs; it contains half of all blood related drugs (B) and three quarters of 
hormonal preparations (H). Clusters II and IV on the contrary are dominated by cardiovascular 
drugs (C), while this class is almost absent from the other groups. Respiratory system drugs 
are only found in clusters II and IV. 
The fact that clusters II and IV show more similarities than the other clusters must be put into 
relation with the fact that these two clusters correspond to large scopes, while clusters I and 
III correspond to small specific scopes. Therefore, there appears to be a relationship between 
the composition and extent of a drug scope and its therapeutic properties. This observation 
reinforces the potential role of scopes as an indicator of drug action and effects in a systems-
wide context. 
A complementary analysis of the relationships between drug scopes and therapies was realized 
by constructing a network of drug scopes (see Methods). Complex interwoven interactions can 
be analyzed in networks by identifying the cohesive building blocks of the system. Cohesive 
subgraphs are sets of nodes with high density of edges in their network neighborhood. We 
applied an iterative decomposition method to uncover k-core subnetworks, defined as the 
largest subgraphs where every node has at least degree k. Figure 8 shows the decomposition 
of a network of drug scopes, for a threshold of 0.2 in the Jaccard distance between scopes and 
in the human irreversible case. Each colored node represents a different core partition. Highly 
connected drugs are located in innermost cores where overlapping with complete therapy 
graphs is more evident. The overlapping of therapy cliques with k-core subgraphs confirms 
links between the composition of scopes and the effects of drugs. 
Discussion  
It is a widely accepted fact that new approaches are needed to facilitate and increase the 
quality of the drug target identification and drug development processes. High levels of 
investment by pharmaceutical companies in recent years have not been followed by a 
corresponding increase in discovery and commercialization of new drugs, and the traditional 
reductionist approach of drug development is seen as a possible cause for this lack of success. 
Many diseases are multifactorial and can not be handled by targeting only isolated molecules, 
but systemic aspects need to be taken into account. The toxicity and harmful side-effects of 
some drugs can also be accounted to by a failure of considering drug action in an integrated 
and systemic way. When a molecular target is perturbed by a drug, effects are not limited to 
that target but potentially extent to the whole interaction network connected to it. It therefore 
becomes more and more necessary to study drug action with a systems biology perspective, 
and important efforts are needed to construct and characterize the interaction networks 
connecting drug targets to all components of a biological system. 
The metabolic network is one of these interaction networks, and drug scopes provide a 
straightforward and efficient tool to construct them and to analyze their properties. We have 
shown that drug scopes can vary greatly in size and distribution. When a drug has a small 
scope, its action is necessarily restricted to a small set of reactions and compounds. Whether 
this feature should be considered as enviable or not is open to discussion, and most certainly 
depends on the context. When a disease is due to the malfunction of a specific process or the 
lack of a specific metabolic compound, a small scope would a priori be preferable, since it 
guarantees that no harmful side-effects are induced by the drug. Large scopes are more 
difficult to assess: on the one side, a drug with a large scope is potentially more efficient in 
combating a multifactorial disease, as its effects can extend far beyond the immediate targets. 
On the other side, because it is difficult so far to quantify such large-scale effects, it cannot be 
excluded that they might include negative consequences for the organism. A wishful goal for 
the future should therefore involve moving beyond this type of qualitative view of drug-
metabolism interactions towards a more quantitative view. For example, being able to predict 
which reactions and compounds of the drug scope are enhanced or repressed by the drug’s 
action could lead to a whole new level of knowledge. 
It is remarkable too that correlations can be observed between drug scopes and therapeutic 
properties of drugs. This observation strengthens the relevance of drug scopes in studying a 
drug's action and effects in a systems-wide context. As they discriminate the networks of 
action of different drugs, scopes also offer a discrimination between the consequences of these 
actions. Whether this finding can be turned into a predictive tool, i.e. to determine scopes and 
drug targets with the aim of obtaining effect, remains open to investigation but certainly 
provides an exciting perspective. 
Methods  
Construction of drug scopes  
The Drugbank database is a comprehensive bioinformatics and chemoinformatics resource 
containing detailed information about all US approved drugs and their molecular targets [17]. 
We downloaded the database and identified all drugs having enzymatic targets by extracting 
their Enzyme Commission (EC) numbers. For each of them, we compiled the list of substrates 
and products using both the Kegg [21] and Brenda databases [22]. In the case of unspecific 
reactions having multiple substrates and products, we only selected the most common 
compounds, as uncommon compounds are usually not supported by the scope construction 
application. 
For each drug, the complete set of compounds determined in this way constituted the seeds of 
the drug scope. Oxygen and water were added to the seeds if not already present, as it is 
assumed that these compounds are always available in a human metabolism context. The 
following cofactors were also assumed to be available for metabolic reactions, but they were 
not added to the seeds: ATP, ADP, NAD, NADH, NADP, NADPH, CoA. 
We subsequently used the MetaPath Online application [14] to construct the scopes resulting 
from these seeds. For each drug, we computed four different scopes based on four metabolic 
networks: a reference network corresponding to the union of all species vs. a human network, 
and for each of those a reversible vs. an irreversible topology. Scopes were saved as text files 
for subsequent analysis. 
It frequently occurred that multiple drugs had the same set of enzymatic targets. In this case 
the scopes of these drugs are necessarily identical. In several parts of our analysis such 
duplicate scopes were counted only once, so that we used a subset of scopes that are all 
distinct. A list of drugs and their enzymatic targets is provided in Supplementary File 1, where 
drugs with identical targets are highlighted in the same color. 
Clusters of drug scopes 
We used the Jaccard distance between sets to define a measure of dissimilarity between 
scopes. For two scopes A and B, the Jaccard distance is 1 - |A∩B|/|A∪B|, where |A∩B| is the 
number of compounds contained in the intersection of A and B, and |A∪B| is the number of 
compounds contained in the union of A and B. If two scopes are identical their Jaccard distance 
is 0; if two scopes have no compound in common their Jaccard distance is 1. 
Hierarchical clustering of drug scopes was calculated with the R statistical computing 
environment using the Jaccard distance as a measure of dissimilarity. The clustering algorithm 
proceeds iteratively, at each stage joining the two most similar clusters, continuing until there 
is just a single cluster. At each stage, distances between clusters are recomputed according to 
the particular clustering method being used. We adopted the complete linkage method which 
defines the distance between any two clusters as the maximum distance between them. A 
cutoff value of 0.5 was used to define clusters. 
Consensus scopes  
Following a definition set by Matthäus et al. [16], the consensus scope of a cluster is the set of 
compounds that are contained in at least 50% of all scopes in the cluster. Consensus scopes 
are useful to visualize the typical properties of a group of drug scopes. Although the threshold 
of 50% is arbitrary, this definition is very robust against variations of the threshold. Most 
consensus scopes of our clusters remain identical when the threshold varies between 30% and 
90%. The same property was observed with consensus scopes of clusters of individual 
compounds [16]. 
Therapeutic properties  
The Drugbank database also contains information about the therapeutic properties and 
applications of each drug. This information follows the Anatomic Therapeutic Chemical (ATC) 
classification. The ATC system is used by the World Health Organization as an international 
standard for drug utilization studies. It divides drugs into different groups according to the 
organ or system on which they act and their chemical, pharmacological and therapeutic 
properties. Drugs are classified into groups at five different levels. The first level of the code 
consists in a letter for the anatomical group, there are 14 such groups. 
Scope network construction 
Using the Jaccard distance as a measure of dissimilarity between scopes, we constructed a 
similarity network composed of scopes as nodes. Two scopes were connected by an edge if the 
Jaccard distance between them was higher than a given threshold. Drugs whose distance to 
any other drug never exceeded the threshold, which would thus constitute isolated nodes, 
were not included in the network representation. 
k-Cores  
Let G = (V, E) be a graph where V is the set of nodes and E is the set of edges. A subgraph H 
= (W, E|W) induced by the set W is a k-core iff ∀v ∈ W, deg(v) > k and H is a maximum 
subgraph with this property [23,24]. Given a graph G, the algorithm of Batagelj & Zaversnik 
determines cores hierarchy by recursively deleting all nodes and connected edges of degree 
less than k. As a result, the remaining graph is the k-core graph. 
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Figure legends 
Figure 1: Distribution of scope sizes. Multiple identical scopes are counted only once. The width 
of intervals is 20 for reference networks (top), 5 for human networks (bottom). 
 
Figure 2: Frequencies of occurrence of compounds in scopes. Multiple identical scopes are 
counted only once. The width of intervals is 2. 
 
Figure 3: Frequencies of occurrence of reactions in scopes. Multiple identical scopes are 
counted only once. The width of intervals is 2. 
 
Figure 4: Consensus scopes of drug groups plotted over a Kegg Atlas genome scale metabolic 
map for the reference reversible metabolic network. Chemical compounds belonging to the 
scope appear as red dots. 
 
Figure 5: Venn diagrams showing overlapping between consensus scopes of clusters in each 
network. 
 
Figure 6: Venn diagrams showing overlapping between drugs belonging to the four main 
clusters in each network. (1) represents cluster I for all four networks. (2) represents cluster II 
for the reference reversible/irreversible and the human reversible networks, cluster III for the 
human irreversible network. (3) represents cluster III for the reference reversible/irreversible 
and the human reversible networks, cluster IV for the human irreversible network. (4) 
represents cluster IV for the reference reversible/irreversible and the human reversible 
networks, cluster V for the human irreversible network. 
 
Figure 7: Top: Pie charts showing the distribution of therapeutic classes in the four main 
groups of drugs. Bottom: Repartition of each therapeutic class through the four groups. Colors 
correspond to identifiers I to IV as indicated below the large pie charts. 
 
Figure 8: Network of drug scopes in the human irreversible case. Nodes of same color belong 
to the same k-core, isolated nodes are not shown. Groups of drugs belonging to the same 
therapy class are highlighted. Similar patterns were observed in the human reversible case. 
Tables 
Table 1: Clusters of drug scopes in the reference reversible network. 
 
Cluster Id 




in consensus scope 
I 37 15 - 
II 163 1963 ATP, NAD+, Pyruvate, Galactose 
III 35 69 Arachidonate 
IV 41 995 Pyruvate, Galactose 
 
Table 2: Clusters of drug scopes in the reference irreversible network. 
 
Cluster Id 
Number of drugs in 
cluster 
Average scope size
Significant compounds in consensus 
scope 
I 40 14 - 
II 154 1606 ATP, NAD+, Pyruvate, Galactose 
III 35 68 Arachidonate 
IV 39 687 Pyruvate, Galactose 
V 1 27 CoA 
VI 3 47 - 
VII 3 35 - 
VIII 1 38 - 
 
Table 3: Clusters of drug scopes in the human reversible network. 
 
Cluster Id 
Number of drugs in 
cluster 
Average scope size
Significant compounds in consensus 
scope 
I 77 9 - 
II 94 339 ATP, Pyruvate, Tyrosine, Galactose 
III 35 40 Arachidonate 
IV 30 130 Pyruvate 
V 12 244 Pyruvate, Tyrosine, Galactose  
VI 8 21 - 
VII 1 44 Tryptophan, Tyrosine 
VIII 4 11 - 
IX 5 21 - 
X 3 22 - 
XI 2 14 - 
XII 2 11 - 
XIII 1 30 - 
XIV 1 33 Tyrosine 
XV 1 16 - 
 
Table 4: Clusters of drug scopes in the human irreversible network. 
 
Cluster Id 
Number of drugs in 
cluster 
Average scope size
Significant compounds in consensus 
scope 
I 62 8 - 
II 24 10 - 
III 85 230 ATP, Pyruvate, Galactose 
IV 35 40 Arachidonate 
V 14 11 - 
VI 15 21 - 
VII 13 27 - 
VIII 5 110 Pyruvate 
IX 8 21 - 
X 1 12 CoA 
XI 1 25 CoA 
XII 2 53 Tryptophan 
XIII 3 21 - 
XIV 2 14 - 
XV 1 16 - 
XVI 2 11 - 
XVII 1 24 - 
XVIII 1 30 Tyrosine 
XIX 1 16 - 
 
Supplementary Files 
Supplementary File 1: List of drugs and their enzymatic targets sorted by EC numbers. Drugs 
sharing the same targets are highlighted in the same color. 
 
Supplementary File 2: Composition of drug clusters for the four metabolic networks. 
 








